Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis and remains incurable. The choice and sequence of therapy for patients with mCRPC is challenging and influenced by various factors, such as treatment history, the presence of actionable genomic alterations or biomarkers, side effects, comorbidities, patient preference, etc. This mini-review will briefly summarise the available data of the latest clinical trials on the use of poly (ADP-ribose) polymerase inhibitors (PARPi) and prostatespecific membrane antigen (PSMA)-targeted therapy that impacted clinical practice.
